Cancer prevention involving reduction or elimination of human exposure to environmental carcinogens may not always be possible. Inhibition of the development of cancer by the administration of anticarcinogenic agents may offer a practical alternative for reducing human cancer burden. However, the successful utilization of chemopreventive interventions will require solid mechanistic understanding of the action(s) of these agents. Dithiolethiones are amongst the most broadly effective classes of chemopreventive agents in experimental models; clinical trials also indicate their efficacy in populations exposed to dietary aflatoxins or tobacco smoke. The objectives of this investigation remain to define the mechanisms of chemoprevention afforded by dithiolethiones and related compounds. Highly quantitative animal model systems for interrelating the molecular, biochemical, and biological actions of these chemopreventive agents have been developed and will be used in i) the development and characterization of new, potent dithiolethiones, ii) the identification of novel genes modulated by dithiolethiones, iii) probing the specific contributions of these induced genes to chemoprevention, and iv) the validation of intermediate biomarkers to assess the efficacy of anticarcinogenic interventions. Recent gene discovery activities indicate that dithiolethiones affect the expression of many genes that are likely to repress the cytotoxic and autopromoting actions of carcinogens in addition to their genotoxic ones. Thus, investigations of the cytoprotective mechanisms of dithiolethiones form the primary focus of this renewal. Functional consequences of induction of protective pathways by dithiolethiones, including STAT signaling, proteasome activation, and carcinogen metabolism by aldehyde reductases, will be probed through a series of in vitro assays and studies in transgenic animals using a panel of validated intermediate biomarkers. Structure-activity studies of a large dithiolethione library will probe their tissue and cell-type specific pharmacodynamic action in a reporter mouse to better inform matching of agents with target tissues. This library will also be screened for analogs in addition to oltipraz that inhibit and reverse the development of fibrosis and cirrhosis, a key step in liver cancer. Collectively, these studies will further the goal of effectively using dithiolethiones as protective agents in human populations exposed to environmental toxicants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA039416-19
Application #
6770848
Study Section
Special Emphasis Panel (ZRG1-TCB (02))
Program Officer
Malone, Winfred F
Project Start
1985-09-01
Project End
2009-01-31
Budget Start
2004-02-26
Budget End
2005-01-31
Support Year
19
Fiscal Year
2004
Total Cost
$528,154
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wible, Ryan S; Tran, Quynh T; Fathima, Samreen et al. (2018) Pharmacogenomics of Chemically Distinct Classes of Keap1-Nrf2 Activators Identify Common and Unique Gene, Protein, and Pathway Responses In Vivo. Mol Pharmacol 93:297-308
Johnson, Natalie M; Egner, Patricia A; Baxter, Victoria K et al. (2014) Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold. Cancer Prev Res (Phila) 7:658-65
Fasullo, Michael; Smith, Autumn; Egner, Patricia et al. (2014) Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae. Mutat Res Genet Toxicol Environ Mutagen 761:18-26
Kensler, Kevin H; Slocum, Stephen L; Chartoumpekis, Dionysios V et al. (2014) Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice. Toxicol Sci 139:293-300
Kensler, Thomas W; Egner, Patricia A; Agyeman, Abena S et al. (2013) Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 329:163-77
Takaya, Kai; Suzuki, Takafumi; Motohashi, Hozumi et al. (2012) Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53:817-27
Wogan, Gerald N; Kensler, Thomas W; Groopman, John D (2012) Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 29:249-57
Koissi, Niangoran; Shah, Niti H; Ginevan, Brandon et al. (2012) Lactone metabolite common to the carcinogens dioxane, diethylene glycol, and N-nitrosomorpholine: aqueous chemistry and failure to mediate liver carcinogenesis in the F344 rat. Chem Res Toxicol 25:1022-8
Fahey, Jed W; Talalay, Paul; Kensler, Thomas W (2012) Notes from the field: ""green"" chemoprevention as frugal medicine. Cancer Prev Res (Phila) 5:179-88
Kensler, Thomas W; Roebuck, Bill D; Wogan, Gerald N et al. (2011) Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci 120 Suppl 1:S28-48

Showing the most recent 10 out of 116 publications